Title |
Spotlight on prostate cancer: the latest evidence and current controversies
|
---|---|
Published in |
BMC Medicine, March 2015
|
DOI | 10.1186/s12916-015-0311-x |
Pubmed ID | |
Authors |
Sigrid Carlsson, Andrew Vickers |
Abstract |
Recent decades have seen dramatic changes in the management of prostate cancer based on novel research findings. Prostate-specific antigen (PSA) screening has been introduced, and then recently modified to include new strategies and biomarkers. Management of advanced disease has been transformed by the rapid introduction of new agents. We have moved from a "one-size-fits-all" approach in prostate cancer management to multidisciplinary strategies tailored to the individual patient and his specific cancer. This editorial marks the launch of the article collection Spotlight on prostate cancer (http://www.biomedcentral.com/bmcmed/series/SPR), and here, guest editors Sigrid Carlsson and Andrew Vickers give an overview of the past, present, and future of prostate cancer research and management. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 30% |
United States | 2 | 20% |
Canada | 1 | 10% |
Unknown | 4 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 60% |
Practitioners (doctors, other healthcare professionals) | 3 | 30% |
Scientists | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Nigeria | 1 | 2% |
Unknown | 45 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 9 | 20% |
Student > Bachelor | 7 | 15% |
Researcher | 7 | 15% |
Student > Doctoral Student | 5 | 11% |
Student > Ph. D. Student | 5 | 11% |
Other | 10 | 22% |
Unknown | 3 | 7% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 17 | 37% |
Nursing and Health Professions | 6 | 13% |
Biochemistry, Genetics and Molecular Biology | 4 | 9% |
Agricultural and Biological Sciences | 3 | 7% |
Immunology and Microbiology | 3 | 7% |
Other | 9 | 20% |
Unknown | 4 | 9% |